# Dual Therapy With Dabigatran/Ticagrelor Versus Dual Therapy With Dabigatran/Clopidogrel in ACS Patients With Indication for NOAC Undergoing PCI

Study · id `cardio:ct-nct04688723` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04688723](<https://clinicaltrials.gov/study/NCT04688723>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT04688723

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease; Stroke; Heart rhythm problems; Acute care and long-term living  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 1000 participants.

## Technical summary

Registry record NCT04688723. Randomized; no masking; primary purpose treatment. Start 2020-12-23 (actual); primary completion 2022-12-31 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 1000 participants (planned count; ClinicalTrials.gov record NCT04688723, source copy `cardio:ctgov-nct04688723-2021-04-30`, retrieved 2026-10-26)
- Started: 2020-12-23 (actual) (ClinicalTrials.gov record NCT04688723, source copy `cardio:ctgov-nct04688723-2021-04-30`, retrieved 2026-10-26)
- Primary completion: 2022-12-31 (anticipated) (ClinicalTrials.gov record NCT04688723, source copy `cardio:ctgov-nct04688723-2021-04-30`, retrieved 2026-10-26)
- Completion: 2023-07-01 (anticipated) (ClinicalTrials.gov record NCT04688723, source copy `cardio:ctgov-nct04688723-2021-04-30`, retrieved 2026-10-26)
- Countries: Netherlands (ClinicalTrials.gov record NCT04688723, source copy `cardio:ctgov-nct04688723-2021-04-30`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04688723-2021-04-30`, retrieved 2026-10-26)

## The registry's words

- Brief title: Dual Therapy With Dabigatran/Ticagrelor Versus Dual Therapy With Dabigatran/Clopidogrel in ACS Patients With Indication for NOAC Undergoing PCI
- Acronym: RE-DUAL PCI
- Condition: Coronary Artery Disease
- Condition: Myocardial Ischemia
- Condition: Myocardial Infarction
- Condition: Atrial Fibrillation
- Intervention (Drug): Dabigatran + Ticagrelor
- Intervention (Drug): Dabigatran + clopidogrel
- Lead sponsor: Zuyderland Medisch Centrum
- Lead sponsor class: OTHER
- Collaborator: Boehringer Ingelheim
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Arrhythmia (heart rhythm problems) (`cardio:arrhythmia`)
- Registry condition terms include this condition: Atrial fibrillation (AF) (`cardio:atrial-fibrillation`)
- Registry condition terms include this condition: Coronary artery disease (`cardio:coronary-artery-disease`)
- Registry condition terms include this condition: Heart attack (myocardial infarction) (`cardio:myocardial-infarction`)
- Registry lists this organization as a collaborator: Boehringer Ingelheim (`cardio:boehringer-ingelheim`)

## Provenance

Content hash: baaf9b5c081a43c45d66292a75d795233cdd8d8b44b7647bb6c6b17f266e0de5
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
